Breast Conserving - Lumpectomy Surgery

Keeping the breast is not a compromise. The survival data point the other way.

A Swedish national study of 48,986 women found better overall survival after breast conservation with radiation than after mastectomy, and the gap held after adjusting for other illness, education and income.

Send the biopsy report and the imaging you already have. A surgeon reads them and tells you whether your tumor can be treated with conservation, before you spend anything on travel. The review costs nothing and carries no obligation, and a coordinator answers in your own language.

Breast conserving surgery removes the tumor together with a thin cuff of normal tissue around it and leaves the rest of the breast, the nipple and the skin in place. Your surgeon may call it a lumpectomy, a wide local excision, a partial mastectomy or a segmental mastectomy. All four names describe the same idea, so the paperwork from two hospitals can look as though it describes two different operations when it is not, and the cuff of normal tissue around the tumor does the real work in all four of them, so the operation amounts to more than the removal of a lump. Cancer cells spread outward from the visible tumor in a way no scan resolves, so the surgeon takes a margin of apparently healthy breast with the specimen and the pathologist then checks whether cancer reaches the inked outer surface. What comes out is a piece of breast, oriented with stitches or clips so that the laboratory can say which face of it was pointing toward the chest wall and which toward the skin. That orientation lets a second operation, where one proves necessary, go back to a single face instead of taking the whole area again.

The operation treats the cancer in the breast. What happens to the lymph nodes under your arm, and whether chemotherapy or hormone treatment joins the plan, are separate questions decided on separate evidence, and both are answered further down this page.

No, and that answer has moved further in your favor over the last decade. The randomized trials of the 1970s and 1980s established that the two operations gave equal survival, and that equality is what most clinicians were taught, yet large modern cohorts treating women with the drugs and the radiation techniques available now keep finding something rather different from equality. A Swedish national study of 48,986 women treated between 2008 and 2017 compared breast conservation with radiation against mastectomy with and without radiation, adjusted for the two confounders that usually explain such differences away, meaning other illness and socioeconomic position, and still found overall survival worse after mastectomy without radiation (hazard ratio 1.79) and after mastectomy with radiation (hazard ratio 1.24). Five-year overall survival across the whole cohort was 91.1 percent and breast cancer specific survival was 96.3 percent. A 2024 meta-analysis in BJS Open pooled 35 observational studies covering 909,077 patients and reached the same direction of effect, with a pooled hazard ratio of 0.72 favoring conservation with radiation.

Read that carefully, because the strength of the claim matters. These are observational studies and not randomized trials. The authors of both say so plainly. Healthier women get offered breast conservation more often in the first place, and that alone shifts the numbers. The certainty of the evidence in the meta-analysis was graded very low. One thing can be said with confidence, and it happens to be the thing you need. No serious body of evidence shows worse survival when the breast is kept, and several large recent datasets show the opposite. Choosing mastectomy for a tumor that could have been treated with conservation buys nothing in survival.

That still leaves reasons to choose mastectomy, and they are real ones. A woman who would rather avoid five weeks of travel for radiation, or who carries a BRCA mutation and wants both breasts removed to reduce future risk, or whose tumor is genuinely too large for the breast, is making a sound decision. She should be making it for those reasons, and never because somebody implied the smaller operation was the less thorough one.

Local return of the cancer in the treated breast gives you the second number you need. In the FAST-Forward trial, which followed 4,096 women after breast surgery and radiation, the five-year rate of cancer coming back in the treated breast was 2.1 percent with the standard three-week radiation schedule.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Tumor size on its own never decides this.

Set the tumor against the size of the breast instead, because the result turns on how much breast is left once the cancer and its margin are gone. A three centimeter cancer in a large breast is a straightforward conservation case. The same three centimeters in a small breast may not.

Two of those deserve unpacking, because women are turned away for them unnecessarily. Cancer in two separate spots of the same breast used to be an automatic mastectomy. Surgeons now treat it with two excisions when both sit in the same quadrant and the cosmetic result will hold, which is a change in practice that has not reached every clinic. And a large tumor is frequently a candidate after chemotherapy given up front, before the operation, which is exactly what that sequence is for, because a cancer that shrinks under treatment can move from mastectomy territory into conservation territory in three or four months.

Describing how the decision actually gets made helps here, because from the outside it looks like one surgeon making a call, and it never is. The tumor size and position come from the mammogram and the ultrasound, a breast MRI is added where the extent is unclear or the cancer is lobular, the biopsy gives the type and the receptor status, and those findings go to a meeting where a surgeon, a radiologist, a pathologist, a medical oncologist and a radiation oncologist look at the same images together. That meeting produces a recommendation with a reason attached, and you are entitled to hear the reason. If a hospital tells you mastectomy without telling you why conservation was ruled out, that is a question to ask rather than an answer to accept.

Age deserves a line of its own, because it is the assumption that costs women the most. A woman of 75 in good health with a small hormone-sensitive cancer is a textbook candidate for keeping her breast, and being offered a mastectomy because it seems simpler is not a clinical argument. In the other direction, being 35 is not a reason to remove a breast either. Younger women do have a higher rate of the cancer returning in the treated breast, which is real, and the 2014 margin consensus specifically looked for evidence that they need wider clearance and did not find it.

Hearing no counts as an answer too, and you want it before you buy a flight.

Send the biopsy report, the mammogram, the ultrasound and any breast MRI, and a surgeon reads them and tells you which of the two operations your case actually falls into. If it comes back as mastectomy, you have that answer while still at home and can decide what to do with it. That review costs nothing and commits you to nothing.

Expect one to two hours under general anesthesia. It runs in this order, so nothing on the day catches you out.

You wake in recovery with a dressing. No drain, in most cases, and a breast that feels tight and bruised, with sharp pain uncommon. Most women go home the same day or after one night. The wire, if you had one, came out with the specimen.

One phrase carries the whole standard, and it reads no ink on tumor. When the specimen reaches the laboratory its outer surface is painted with dye, then sliced and examined, and the margin is called negative when no cancer cell touches the painted surface. That standard was set by a Society of Surgical Oncology and American Society for Radiation Oncology consensus panel in 2014, working from a pooled analysis of 33 studies and 28,162 patients, and it replaced decades of local rules demanding one, two or five millimeters of clearance. Wider margins bought nothing, and that finding is what changed the practice. Cancer reaching the ink roughly doubles the chance of the disease returning in that breast, and that extra risk is not canceled out by favorable tumor biology, by hormone treatment or by an extra radiation boost. Going wider than no ink on tumor, on the other hand, did not lower the recurrence rate any further, and it did not help younger women, women with lobular cancers or women with an extensive in situ component either, which were exactly the groups people assumed needed a bigger clearance. The practical consequence for you is fewer second operations, better looking breasts and no loss of safety.

Second operations still happen. Not often. If the final report, which takes three to five working days, shows cancer at the ink, the standard response is a re-excision, meaning a short second operation that removes an extra shaving from the one face where the problem was. It takes less time and less tissue than the first operation. The cavity already exists, the original specimen was oriented, and the surgeon therefore knows exactly which face to shave.

Ask about this before you travel, because a positive margin is the single most common reason a breast cancer trip runs longer than planned, and the question that gets you a useful answer is what happens, practically and financially, if the report comes back positive on the day you were due to fly home. The answer here is that the final pathology is timed to arrive while you are still in Istanbul for your post-operative check, so a re-excision, if one is needed, is done on this trip rather than becoming a second journey.

Women fear lymphedema here, and they are right to.

Clearing all the nodes from the armpit leaves a proportion of women with an arm that swells permanently, and that swelling is harder to live with day to day than the breast surgery ever was. Surgeons now do that clearance far less often.

Z0011 did most of the work here. It randomized 891 women who had a lumpectomy, whole breast radiation and one or two sentinel nodes containing cancer, giving half of them a full armpit clearance and half of them nothing further. At ten years, overall survival was 86.3 percent in the group who had no clearance and 83.6 percent in the group who did, which met the trial's test for non-inferiority, and disease-free survival was 80.2 percent against 78.2 percent. Between years five and ten, one regional recurrence appeared in the no-clearance group. One.

So a woman having a lumpectomy for a T1 or T2 cancer, without swollen nodes she can feel, whose sentinel biopsy finds cancer in one or two nodes, and who is going on to have whole breast radiation and systemic treatment, does not need her armpit cleared.

Those women make up a large share of everyone having this operation. Adherence to the finding varies a great deal between hospitals, so put the question to your surgeon directly.

Full clearance still earns its place in specific situations. Three or more positive sentinel nodes, cancer palpable in the armpit before surgery and confirmed on needle biopsy, disease that has grown outside the capsule of a node, and cases where whole breast radiation is not going to be given all point back to it. If that is your situation, the physiotherapist should see you before discharge, so the shoulder exercises and the arm care that keep the swelling risk down start immediately.

Radiation to the remaining breast belongs to the treatment as much as the operation does. The two together are what the trials tested and what every survival figure on this page describes, and a woman who has the surgery and declines the radiation has stepped outside the group those numbers came from. That matters more here than it does for a woman being treated at home, because the radiation is the part of the plan that ties you to one place for several weeks, and it is therefore the part most often quietly dropped when the travel gets complicated.

That commitment has shrunk enormously.

Whole breast radiation used to mean twenty-five daily sessions across five weeks. Then fifteen sessions over three weeks became the standard, and cancer control held exactly as it had at the longer schedule, which is the finding that made everyone ask how much further the course could be compressed. FAST-Forward tested one week against three, randomizing 4,096 women across 97 centers to 40 Gy in 15 fractions, 27 Gy in 5 fractions or 26 Gy in 5 fractions, and reported at five years that 26 Gy delivered over one week was non-inferior for cancer control and no worse for the appearance and feel of the breast, while the slightly higher 27 Gy schedule did produce more tissue effects. Five sessions in one week is now an evidence-based option for the right patient rather than a shortcut. Which schedule suits you depends on the tumor, on whether the lymph node areas need treating as well and on whether a boost dose to the tumor bed is planned, and a radiation oncologist makes that call rather than a surgeon.

You have a real choice about where it happens. Radiotherapy is delivered at Biruni Hospital on the same site as the surgery, so staying on and finishing the whole treatment here in one trip is possible, and it keeps the same team and the same records throughout. Going home and having the radiation locally is equally valid, and it is what many women prefer once the operation is behind them. If that is your plan, say so at the first consultation, because the discharge summary, the pathology report, the operation note and the clip positions are then prepared as a package your own oncologist can act on without repeating anything.

One timing rule matters more than any other. Radiation should start within eight weeks of surgery when no chemotherapy is planned in between, so if you are arranging it at home, arrange it before you leave rather than after you land.

Lumpectomy causes less upheaval than most cancer operations, and serious complications after it stay uncommon. What does happen appears below, with the standard management set against each one.

Radiation brings its own effects, which arrive later. Skin redness and soreness like sunburn during treatment and for a couple of weeks after it, tiredness that builds through the course, and a gradual firming and slight shrinking of the treated breast over the year that follows. Only the firming lasts.

Women consistently describe this operation as easier than they had braced for, and then find the tiredness lasts longer than they expected. Both halves of that are normal.

This table scrolls sideways on a narrow screen. Swipe or drag to see every column.

Flying deserves its own sentence, because it is the question that decides your return ticket. Short flights are generally comfortable from around ten days and most women traveling long haul are cleared at two to three weeks, once the wound is sealed and there is no sign of infection or a growing collection. The date is written on your discharge summary after somebody has looked at the wound, and it moves if the wound gives any reason to move it. Book a changeable ticket.

Tissue in the laboratory tells you things no scan could.

Sometimes what it says changes what happens next. Cancer at the ink means a re-excision. More disease than the imaging suggested, spread through the breast, occasionally means the conversation turns to mastectomy after all. Cancer in three or more sentinel nodes means the armpit is dealt with more thoroughly. And the receptor and gene tests done on the specimen decide whether chemotherapy, hormone treatment or a targeted drug joins the plan.

For a woman who flew in for an operation and expected to fly home afterwards, that is the frightening scenario, because it is the one where the treatment stops being a discrete event and becomes a course.

Both radiotherapy and chemotherapy are delivered at Biruni Hospital, on the same site as the surgery, which means the practical answer to that fear is straightforward. If the pathology calls for either, you can continue with the same team, in the same building, with the imaging and the operation note and the pathology already in one record and nothing needing to be requested from anyone or repeated. No referral, no transfer of files, no waiting list at a second institution. The alternative stays fully open, and it is the one many women choose. Going home and having the follow-on treatment with your own oncologist is a perfectly sound plan, and the handover written for it names the exact regimen recommended, the pathology in full, the clip positions for the radiation planning and the surgeon's contact, so your own doctor starts from a complete file instead of a discharge sheet, and starts on the day it lands rather than after a month of requesting records from abroad.

Ask which of those two paths a hospital assumes when it quotes you, because a quote built around the surgery alone reads very differently once a course of treatment is added to it.

No figure appears on this page, and coyness has nothing to do with it. What breast cancer treatment costs depends on what the treatment turns out to be, and that is decided by a pathology report which does not exist yet on the day you are comparing hospitals. Any number published here would be wrong for nearly everyone reading it, and it would start every conversation you have afterwards in the wrong place, with you defending a figure instead of describing your own case.

Learning to read the quotes you are sent serves you far better. These things genuinely move the total for this operation.

Whether the armpit is handled with a sentinel node biopsy or a full clearance, since the second is a longer operation with a longer stay. Whether reshaping the breast is included, because oncoplastic work adds theater time. Whether the wire or marker placement, the specimen X-ray and any frozen section during the operation are inside the figure or billed separately. How many nights on the ward the quote assumes. Whether a re-excision, if the margin comes back positive, is covered or charged again. And whether radiotherapy or chemotherapy is included at all, or whether the number covers only the surgical admission. Your own circumstances move it too, in ways that are easy to overlook. Diabetes, heart or lung disease, obesity and blood thinning medication all change the anesthetic assessment and the length of stay. Previous surgery or radiation to the same breast makes the operation longer. A tumor that needs chemotherapy before surgery turns a single trip into a longer plan.

Packages published by Turkish hospitals and medical travel agencies for this operation typically cover the airport transfer, the pre-operative tests, the surgeon and anesthesia fees, the theater and the ward nights, an interpreter, and the follow-up appointments before you fly. They typically exclude flights, travel insurance, extra nights beyond the plan, intensive care that was not planned, and the treatment of any complication. Read your quote against that list instead of against another quote. Start with the exclusions.

A number that means anything comes from a clinician who has read your reports and your imaging. That review costs nothing here, carries no obligation, and gives the only honest route to a figure that still holds when you arrive.

Plan for two to three weeks in Istanbul if you are having the surgery alone. That covers the consultation and any imaging that needs repeating, the operation, one night or a day case admission, the wound check, the pathology result and the conversation about what it means, and the re-excision if the margin needs one. Staying on for radiation adds one to three weeks depending on the schedule, and chemotherapy is a longer plan discussed separately.

The hospital assigns you a coordinator from your first message, and she stays with you through discharge. The international patients team works in English, Arabic, French, Russian, Serbian, Romanian and Spanish, and interpreting in other languages is arranged on request, which matters most in two specific conversations, being the consent discussion before the operation and the results conversation afterwards, where a word misunderstood changes a decision.

Patient rooms have a companion bed, so one person stays in the room with you overnight for the whole admission. Accommodation for you and your companion for the nights either side of the admission is arranged by the international patients office, along with the airport transfer and the transport between hotel and hospital. Halal, vegetarian and diabetic diets are handled by the hospital kitchen, and there is a prayer room on site.

Requests for a female surgeon go to the department and are accommodated wherever the rota allows. Put it in your first message.

For the visa, the international patients office issues an appointment confirmation and an invitation letter naming the hospital and your treating doctor, which is the document most consulates ask for with a medical visa application. It goes out roughly ten days before travel, and consulates differ enormously in how long they then take, so give the international patients office your dates the moment they are fixed rather than once the flights are already booked.

Then you fly home, and this is the part competitor pages go quiet about.

Your coordinator stays reachable on the same WhatsApp number after you land, so a photograph of a wound that looks wrong at two in the morning goes to someone who already knows your case, and not into a general inbox. Sutures dissolve on their own and need nothing done to them. You leave with the operation note, the full pathology report, the receptor and gene test results, the clip positions and the recommended plan, in a form your own doctor can act on. If radiation is happening at home, the timing window is written down and the file goes out addressed to your oncologist, and the surveillance that follows, meaning an annual mammogram of the treated breast plus an examination starting roughly a year after the radiation ends, belongs to any breast unit near you. Anything new in that breast gets checked promptly. A lump, a thickening, a change in the skin or a discharge earns an appointment of its own instead of a mention at the next scheduled visit.